Tetrahydrobiopterin (BH4) is an essential cofactor for endothelial nitric oxide synthase (eNOS) function and NO generation. Augmentation of BH4 levels can prevent eNOS uncoupling and can improve endothelial dysfunction in vascular disease states. However, the physiological requirement for de novo endothelial cell BH4 biosynthesis in eNOS function remains unclear. We generated a novel mouse model with endothelial cell-specific deletion of GCH1, encoding GTP cyclohydrolase 1, an essential enzyme for BH4 biosynthesis, to test the cell-autonomous requirement for endothelial BH4 biosynthesis in vivo. Mice with a floxed GCH1 allele (GCH1 fl/fl ) were crossed with Tie2cre mice to delete GCH1 in endothelial cells. GCH1 fl/fl Tie2cre mice demonstrated virtually absent endothelial NO bioactivity and significantly greater O 2
T etrahydrobiopterin (BH4) is an essential cofactor for the nitric oxide synthase (NOS) enzymes. 1 When BH4 availability is limiting, NO generation becomes uncoupled from l-arginine oxidation, resulting in superoxide radical (O 2 •-) rather than NO production. 1 Substantial evidence suggests that reduced vascular BH4 bioavailability contributes to the pathogenesis of endothelial dysfunction. 1 For example, BH4 levels in vascular tissue from diabetic mice, apolipoprotein E knockout mice hypercholesterolemic rabbits, and patients with diabetes mellitus are significantly reduced and associated with reduced NO-mediated endothelial function. [2] [3] [4] [5] Pharmacological supplementation with the BH4 precursor sepiapterin can improve endothelial function in various vascular disease states. 3, 6 Biosynthesis of BH4 is catalyzed by GTP cyclohydrolase I (GTPCH), encoded by GCH1. Recent studies have shown that GCH1 expression is a key determinant of endothelial cell BH4 levels and endothelial NOS (eNOS) regulation. 7, 8 Transgenic overexpression of GCH1 in mice is able to improve endothelial function in vascular disease states, such as pulmonary hypertension, 9 diabetes mellitus, 10 and atherosclerosis. 11 Although these studies implicate reduced or augmented BH4 in vascular disease pathogenesis, the physiological requirement for endothelial BH4 in the regulation of eNOS-derived vascular NO generation, or other eNOS-derived signaling mechanisms, remains unanswered. Furthermore, whether cell-autonomous endothelial cell BH4 synthesis by GTPCH is necessary for physiological eNOS function, as distinct from endothelial cell uptake from plasma or other sources, is important in guiding therapeutic strategies that target eNOS function in vascular disease states, including hypertension.
Previous studies of the importance of BH4 biosynthesis have used systemic pharmacological inhibitors of GTPCH, 12, 13 or the hph-1 hyperphenylalaninemic mouse, generated by N-ethyl-N-nitrosourea mutagenesis, that has moderate systemic BH4 deficiency because of reduced gene expression from the GCH1 locus. 6, 9 However, in the hph-1 mouse, global BH4 deficiency has systemic effects in multiple cell types, such as neurotransmitter synthesis and autonomic function, 14, 15 thus confounding the interpretation of endothelial cell BH4 effects on vascular function and blood pressure control by eNOS. We hypothesized that endothelial cell GCH1 expression, and BH4 synthesis, is cell-autonomous requirements for eNOS regulation in vivo. To test this hypothesis, we generated a novel mouse model with endothelial cell-specific deletion of GCH1 and tested the effects on eNOS enzymatic coupling, vasomotor function, and blood pressure regulation.
Methods
For detailed Methods, see online-only Data Supplement.
Generation of Endothelial Cell-Targeted GCH1 Knockout Mice
We generated a novel mouse model of endothelial cell-specific BH4 deficiency, the GCH1 fl/fl Tie2cre mouse. Exons 2 and 3 of GCH1, encoding for the active site of GTPCH, were flanked by loxP sites in a targeting construct that was used to produce GCH1 fl/fl mice after homologous recombination in embryonic stem cells ( Figure 1A) . These mice were crossed with Tie2cre transgenic mice 16 to produce GCH1 fl/fl Tie2cre mice where GCH1 is deleted specifically in endothelial cells ( Figure 1B) , generating an endothelial cell BH4-deficient mouse. Mice were genotyped by polymerase chain reactions using DNA prepared from ear biopsies. Mice were housed in ventilated cages with a 12-hour light/dark cycle and controlled temperature (20-22°C) , and fed normal chow and water ad libitum. Male GCH1 fl/ fl Tie2cre mice and their GCH1 fl/fl littermates were used for all experiments at 12 to 22 weeks. All studies were conducted in accordance with the UK Home Office Animals (Scientific Procedures) Act 1986 (HMSO, London, United Kingdom).
Results

Endothelial Cell-Targeted GCH1 Deletion Reveals a Cell-Autonomous Requirement for Endothelial Cell BH4 Biosynthesis
We generated matched litters of GCH1 fl/fl Tie2cre and GCH1 fl/fl mice (hereafter referred to as wild type) by crossing male GCH1 fl/fl Tie2cre and female GCH1 fl/fl mice. Body weights between the groups were similar (30.9±1.13 g in wild-type and 30.8±1.31 g in GCH1 fl/fl Tie2cre; n>10 per group). Genomic polymerase chain reaction demonstrated efficient excision of the floxed GCH1 allele in isolated primary endothelial cells from GCH1 fl/fl Tie2cre mice ( Figure 1B) .
Western blot analysis confirmed that GTPCH protein was significantly reduced in aortas from GCH1 fl/fl Tie2cre mice when compared with that from wild-type controls (P<0.01; Figure 1C ). In GCH1 fl/fl Tie2cre mice, BH4 levels in endothelial-rich tissues, such as lung, heart, and aorta, were significantly reduced when compared with wild-type controls ( Figure 1D ). Furthermore, BH4 levels were reduced by ≈75% in endothelial-denuded aortas from wild-type mice. In contrast, removal of endothelium in GCH1 fl/fl Tie2cre aortas did not significantly reduce BH4 levels (P<0.05; Figure 1E ). In non-endothelial cell-rich tissues, such as liver and kidney, there was no difference in BH4 levels between wild-type and GCH1 fl/fl Tie2cre mice. Importantly, plasma BH4 levels were similar between the groups, indicating that endothelial cell BH4 biosynthesis by GTPCH does not contribute significantly to plasma BH4 levels. Despite marked BH4 deficiency, absolute BH2 levels in aortas, lung, and heart were comparable between the genotypes, such that the BH4/BH2 and biopterin ratio was significantly reduced in aortas heart and lung in GCH1 fl/fl Tie2cre mice ( Figure S1 in the online-only Data Supplement).
To test the endothelial cell specificity of GCH1 deletion further, and the effects of endothelial cell loss of BH4 biosynthesis on BH4 levels, we isolated primary mouse endothelial cells using immunomagnetic bead selection. Primary endothelial cells were confirmed as CD31+ CD45-by flow cytometry ( Figure 1F ). In endothelial cells from GCH1 fl/fl Tie2cre mice, GTPCH protein was not detectable by Western blotting, whereas GTPCH was readily detected in wild-type endothelial cells, and the endothelial cell-surface marker CD102 was present equally in endothelial cells from both GCH1 fl/fl Tie2cre and wild-type mice ( Figure 1G ). Measurement of biopterins by high-performance liquid chromatography revealed barely detectable levels of BH4 in primary endothelial cells from GCH1 fl/fl Tie2cre mice ( Figure 1H ). Taken together, these results demonstrate endothelial cell-specific GCH1 knockout in GCH1 fl/fl Tie2cre mice, leading to endothelial cell-specific BH4 deficiency. Furthermore, the finding of marked BH4 deficiency in GCH1 fl/fl Tie2cre endothelial cells, despite normal circulating plasma levels, reveals a cell-autonomous requirement for de novo BH4 synthesis in maintenance of endothelial cell BH4 levels.
Endothelial Cell BH4 Deficiency Leads to eNOS Uncoupling With Increased Superoxide Production and Loss of Endothelial NO Generation
We next determined the effects of endothelial cell-specific BH4 deficiency on eNOS function. We first measured basal O 2
•and other reactive oxygen species (ROS) production in isolated primary endothelial cells by quantification of 2-hydroxyethidium and ethidium production from dihydroethidine, using high-performance liquid chromatography. Both 2-hydroxyethidium and ethidium production were significantly elevated in primary endothelial cells from GCH1 fl/fl Tie2cre mice when compared with wild-type controls (P<0.05; Figure 2A and 2B). Furthermore, there was a significant inhibition of 2-hydroxyethidium and ethidium production in GCH1 fl/fl Tie2cre mice by the NOS inhibitor, N G -nitro-L-arginine methyl ester (L-NAME) (100 μmol/L), whereas no effect was observed in wild-type endothelial cells, suggesting that eNOS is a source of O 2
•production in GCH1 fl/fl Tie2cre endothelial cells.
We determined the spatial distribution of ROS production in aortic tissue sections using dihydroxyethidium fluorescence microtopography. Under basal conditions, GCH1 fl/fl Tie2cre aortas generated 4-fold more endotheliumderived ROS production than wild-type controls (P<0.01; Figure 2C ). In the presence of L-NAME, the level of endothelium-derived ROS production in wild-type aortas was significantly increased when compared with untreated wildtype aortas, suggesting a tonic scavenging effect of NO on O 2
•-(P<0.05). In contrast, endothelial ROS production in GCH1 fl/fl Tie2cre aortas in the presence of L-NAME was significantly decreased when compared with untreated GCH1 fl/ fl Tie2cre aortas (P<0.05), indicating a major contribution from eNOS-derived ROS.
To determine the effects of endothelial cell BH4 deficiency on NO bioactivity, we measured NO bioactivity by 3 different methods. First, we measured l-arginine to l-citrulline conversion using high-performance liquid chromatography with online scintillation detection, to enhance sensitivity and specificity of citrulline detection. We found that eNOS activity was significantly decreased in endothelial cells from GCH1 fl/fl Tie2cre mice when compared with that from wild-type littermates (P<0.05; Figure 3A ). Second, nitrite and nitrate production by aortas was also reduced in GCH1 fl/fl Tie2cre mice when compared with that in wild-type controls, to by guest on July 11, 2017 http://hyper.ahajournals.org/ Downloaded from levels that were barely detectable above baseline (P<0.05; Figure 3B ). Finally, we measured specific NO generation from aortas using EPR detection of NO using the spin trap L-NAME, but was not detectable in GCH1 fl/fl Tie2cre mice aortas ( Figure 3C and 3D). Taken together, these data demonstrate that endothelial cell GCH1 deletion and BH4 deficiency dramatically reduce vascular NO bioactivity.
Endothelial Cell-Specific BH4 Deficiency Leads to Enhanced Vasoconstriction and Impaired Vasodilatation
Next, we investigated the requirement for endothelial cell-specific BH4 synthesis in normal vascular function. Isometric tension studies in isolated aortas demonstrated that the maximal vasoconstriction to 60 mmol/L KCl was comparable between genotypes (6.78±0.27 mN in wild-type and 6.34±0.29 mN in GCH1 fl/fl Tie2cre). However, vasoconstriction to phenylephrine was significantly enhanced in GCH1 fl/fl Tie2cre aortas when compared with that in wild-type aortas (P<0.05; Figure 4A ). This difference was normalized in the presence of L-NAME, indicating that the increased constrictor response in GCH1 fl/fl Tie2cre aortas is mediated by tonic eNOS-derived vasodilatation.
Endothelial-dependent vasodilatation to acetylcholine was modestly impaired but statistically significant in GCH1 fl/fl Tie2cre aortas when compared with that in wild-type aortas (P<0.01; Figure 4B ). Endothelium-dependent vasodilatation in response to the protease activated receptor 2 agonist, SLIGRL ( Figure 4C ), was also impaired in GCH1 fl/fl Tie2cre aortas, suggesting that the impaired vasorelaxation was not because of specific alteration of receptor signaling on endothelial cells of GCH1 fl/fl Tie2cre mice. Endothelium-dependent vasodilatation to acetylcholine in both wild-type and GCH1 fl/fl Tie2cre aortas was abolished in the presence of L-NAME ( Figure  S2A ), indicating that eNOS is the major source of vasodilators in mouse aortas. Endothelium-independent vasodilatation in response to sodium nitroprusside was similar between the groups ( Figure 4D ).
Endothelial BH4 Deficiency Results in H 2 O 2 -Mediated Vasodilatation
We next investigated the mechanisms underlying the vasodilator responses in GCH1 fl/fl Tie2cre aortas, given the loss of NO generation and increased ROS production. In the presence of the H 2 O 2 scavenger, catalase-polyethylene glycol (PEGcatalase; 400 U/mL), endothelial-dependent vasodilatations to acetylcholine were significantly inhibited in GCH1 fl/fl Tie2cre aortas but not in wild-type aortas ( Figure 4E ). PEG-catalase treatment had no effect on the basal vascular tone of either GCH1 fl/fl Tie2cre or wild-type aortas. In the presence of L-NAME, vasodilatation to acetylcholine was abolished in both groups, and further addition of PEG-catalase did not alter the response in either group ( Figure S2A and S2B), suggesting that eNOS is a predominant source of H 2 O 2 . Indeed, direct quantification of H 2 O 2 in stimulated aortic rings with acetylcholine, using the Amplex red assay, revealed increased vascular H 2 O 2 production in GCH1 fl/fl Tie2cre aortas, which was inhibited in the presence of L-NAME ( Figure 4G ). We next investigated whether H 2 O 2 production might lead to changes in eNOS or antioxidant protein expression. In aortas, the protein level of eNOS in GCH1 fl/fl Tie2cre mice was significantly increased (≈2-fold) than that of wild-type controls (P<0.001; Figure 4H ). However, the protein levels of antioxidant enzymes, catalase, Mn superoxide dismutase (SOD), extracellular SOD, and Cu/ZnSOD, were similar between the groups ( Figure S3A-S3D) . Furthermore, the level of phosphorylation A C D B Figure 3 . NO bioactivity in GCH1 fl/fl Tie2cre and wild-type (WT) mice. A, Conversion of 14 C arginine to 14 C citrulline was used as a measure of endothelial nitric oxide synthase activity (eNOS). eNOS activity (N G -methyl-L-arginine [L-NMA] inhibitable) was greatly reduced in primary endothelial cells isolated from GCH1 fl/ fl Tie2cre mice when compared with that from the WT controls (*P<0.05; n=4 per group). B, Nitrite/nitrate production in isolated fresh aorta stimulated with 1 μmol/L acetylcholine (ACh) for 30 minutes. Nitrite/nitrate production (L-NMA inhibitable) in stimulated aortas from GCH1 fl/fl Tie2cre mice was significantly decreased when compared with that from WT controls (**P<0.01; n=7-9 animals per group). C, Representative EPR spectra of mouse aortas stimulated with 1 μmol/L ACh for 90 minutes at 37°C with colloid Fe(DETC) 2 (g values ≈2.04). The characteristic triplet peaks associated with NO-Fe(DETC) 2 signal are shown by the vertical arrows. D, Quantification of NO-Fe(DETC) 2 signal from GCH1 fl/fl Tie2cre and WT aortas with or without stimulated with 1 μmol/L ACh in the presence and absence of 1 mmol/L N Gnitro-L-arginine methyl ester (L-NAME) (*P<0.01 comparing ACh treatment in WT, #P<0.01 comparing L-NAME treatment in ACh WT, $P<0.01 comparing genotype; n=4-6 animals per group).
by guest on July 11, 2017 http://hyper.ahajournals.org/ Downloaded from of eNOS at Thr495, relative to the total eNOS protein content, was comparable between the groups. Phosphorylation of eNOS at Ser1177 was significantly reduced in GCH1 fl/fl Tie2cre aortas when indexed to the total eNOS protein content ( Figure S4) .
To test the specificity of BH4 deficiency, we rescued BH4 levels using sepiapterin that augments BH4 levels via the salvage pathway, independent of de novo BH4 biosynthesis by GTPCH. Ex vivo incubation of GCH1 fl/fl Tie2cre aortas with sepiapterin (10 μmol/L) for 30 minutes restored endothelial vasomotor responses and abolished the effect of PEG-catalase on vasodilatation in GCH1 fl/fl Tie2cre aortas ( Figure 4F ).
Mechanism of H 2 O 2 -Mediated Vasodilatation in GCH1 fl/fl Tie2cre Aortas
We next investigated the mechanism underlying eNOS-derived H 2 O 2 -mediated vasodilatation in GCH1 fl/fl Tie2cre aortas. A combination of potassium channels blockers, apamin (small-conductance Ca 2+ -activated K + channel blocker) and charybdotoxin (nonselective intermediate and large-conductance Ca 2+ -activated K + channels blocker), was used to test K + channel-mediated endothelium-derived hyperpolarizing factor responses. 17, 18 Endothelium-dependent vasodilatation to acetylcholine in GCH1 fl/fl Tie2cre aortas in the presence of apamin and charybdotoxin was similar to wild-type Figure 5C and 5D), indicating the involvement of a sGC-dependent pathway. To test the specificity of this finding, vasodilatation to acetylcholine was assessed in the presence of 30 mmol/L extracellular K + , to inhibit the activity of K + channels and thus endothelium-derived hyperpolarizing factor responses. 18 In the presence of 30 mmol/L extracellular K + , vasodilatation to acetylcholine in GCH1 fl/fl Tie2cre aortas was similar to wild-type aortas but remained significantly inhibited by PEG-catalase ( Figure 5E and 5F). In the presence of ODQ, vasodilatation to acetylcholine in GCH1 fl/fl Tie2cre aortas was inhibited to a similar extent as that observed in the presence of ODQ with PEG-catalase ( Figure 5G and 5H).
These findings indicate that eNOS-derived, H 2 O 2 -mediated vasodilatation in GCH1 fl/fl Tie2cre aortas occurs through a sGC-dependent signaling pathway and not through the activation of endothelium-derived hyperpolarizing factor-sensitive components. Consistent with this finding, the levels of Ser239 phospho-vasodilator-stimulated phosphoprotein (VASP) were measured as readout of protein kinase G (PKG) activity. There was no significant difference in Ser239 phospho-VASP to total VASP protein between wild-type and GCH1 fl/fl Tie2cre aortas, which suggests that H 2 O 2 -derived from eNOS uncoupling in GCH1 fl/fl Tie2cre aortas mediated vasodilatation by increasing phosphorylation of VASP at Ser239 ( Figure S4C ). Responses to exogenous H 2 O 2 -induced vasodilatation in wild-type and GCH1 fl/fl Tie2cre aortas were similar and were inhibited in the presence of ODQ and abolished in the presence of ODQ and PEG-catalase ( Figure S2C and S2D). The combination of apamin and charybdotoxin had little effect on H 2 O 2 -induced vasodilatation ( Figure S2E ).
Impaired Vascular Function in Small Mesenteric Artery in GCH1 fl/fl Tie2cre Mice
We next investigated the requirement for endothelial cell BH4 in vasomotor function in resistance vasculature. Using second-order mesenteric arteries in wire myograph studies, we found increased vasoconstrictions in GCH1 fl/fl Tie2cre mice in response to U46619 (thromboxane A 2 receptor agonist) and phenylephrine (data not shown) when compared with wild-type controls. This difference was normalized in the presence of L-NAME ( Figure S5A ). Furthermore, endothelium-dependent vasodilatations to acetylcholine and SLIGRL were significantly impaired in mesenteric arteries from GCH1 fl/fl Tie2cre mice ( Figure S5B and S5C), whereas endothelium-independent vasodilatations to sodium nitroprusside were not altered ( Figure S5D ). In mesenteric vessels, the protein levels of antioxidant enzymes were comparable between GCH1 fl/fl Tie2cre and wild-type controls ( Figure S3E-S3H ).
Endothelial Cell-Specific GCH1 Deletion and BH4 Deficiency Increase Arterial Blood Pressure
Given the striking changes in eNOS coupling and vasomotor function in GCH1 fl/fl Tie2cre mice, we next determined the requirement for endothelial cell BH4 synthesis in blood pressure regulation, by measuring arterial blood pressure in conscious mice using tail-cuff plethysmography. GCH1 fl/fl Tie2cre mice had significantly higher systolic blood pressure than wild-type littermates (P<0.001; 103.4±1.3 mm Hg in GCH1 fl/fl Tie2cre versus 96.4±0.8 mm Hg in wild type). Heart rate was significantly lower in GCH1 fl/fl Tie2cre mice when compared with that in wild-type littermates ( Figure 6A ). In a further cohort of mice, we measure blood pressure invasively using a Millar catheter. We again found a greater systolic blood pressure in GCH1 fl/fl Tie2cre mice when compared with that in wild-type littermates ( Figure 6B and 6C) . To test the dependence of these blood pressure changes on NOS, we treated mice with L-NAME, added in the drinking water, for 7 days. L-NAME treatment increased blood pressure to a greater extent in GCH1 fl/fl Tie2cre mice, such that blood pressures were no longer different between GCH1 fl/fl Tie2cre mice (113.4±1.8 mm Hg) and wild-type (114.3±1.1 mm Hg), suggesting that increased blood pressure in GCH1 fl/fl Tie2cre mice is NOS mediated ( Figure 6D ). We next measured changes in arterial blood pressure in response to the vasoconstrictor phenylephrine in anaesthetized mice, using a Millar catheter. Phenylephrine caused a significantly greater increase in systolic blood pressure in GCH1 fl/fl Tie2cre mice when compared with that in wild-type controls ( Figure 6E ). To investigate the role of ROS from uncoupled eNOS on hemodynamic response in vivo, we administered the salen-manganese-based SOD/catalase mimetic, EUK-8 (25 mg/kg IP) in anaesthetized mice. EUK-8 significantly reduced systolic blood pressure in wild-type mice, whereas blood pressure was unaltered in GCH1 fl/fl Tie2cre mice ( Figure 6F ).
Discussion
We have created a novel mouse model of endothelial celltargeted GCH1 deletion to test the endothelial cell-specific requirements for BH4 in vascular function and hemodynamic regulation. This novel mouse model reveals several new and important findings. First, endothelial cell-targeted GCH1 deletion leads to endothelial cell BH4 deficiency, despite no significant change in plasma BH4, thus identifying a cell-autonomous requirement for endothelial cell GCH1 and de novo BH4 biosynthesis. Second, endothelial cell-specific BH4 deficiency leads to eNOS uncoupling, with loss of NO bioactivity and increased O 2
•production, resulting in vascular dysfunction with eNOS-dependent vasorelaxation mediated by eNOS-derived H 2 O 2 , acting through the sGC-dependent signaling pathway. Third, the endothelial cell-specific BH4 deficiency resulting from GCH1 deletion leads to hypertension. Taken together, these studies reveal an endothelial cell-autonomous requirement for GCH1 and BH4 in regulation of vascular tone and blood pressure and identify endothelial cell BH4 as a pivotal regulator of NO versus H 2 O 2 as alternative eNOS-derived endothelium-derived relaxing factors.
We have shown that endothelial cell-targeted GCH1 deletion abolishes GTPCH protein expression and de novo BH4 synthesis in primary endothelial cells and leads to substantial reductions in GTPCH and BH4 in aortas, demonstrating that the majority of vascular BH4 is contributed by the endothelium and confirmed by removal of vascular endothelium that reduced BH4 levels by guest on July 11, 2017 http://hyper.ahajournals.org/ Downloaded from in wild-type but not in GCH1 fl/fl Tie2cre aortas. Crucially, there was no difference in plasma BH4 levels between wild-type and GCH1 fl/fl Tie2cre mice, revealing for the first time that the vascular endothelium is not a significant source of circulating biopterins. Furthermore, the maintenance of plasma BH4 levels in GCH1 fl/fl Tie2cre mice was not sufficient to rescue the loss of de novo BH4 synthesis in endothelial cells. This novel observation identifies a cell-autonomous requirement for de novo BH4 synthesis in the maintenance of endothelial cell BH4 levels in vivo. This finding suggests that physiological regulation of endothelial cell BH4 is not influenced by uptake from plasma, despite previous observations that pharmacological administration of high The physiological requirement for endothelial cell BH4 biosynthesis is reflected in the effect on eNOS function. 19 We have previously shown that BH4 bioavailability is a determinant of eNOS function and NO production, 7, 8 and loss of BH4 by oxidation leads to eNOS uncoupling and vascular dysfunction in hypertension. 3 However, the physiological requirement for endothelial cell BH4 in these settings remains unclear because loss of vascular BH4 could be a cause of endothelial dysfunction or could be the consequence of vascular disease. We have now shown that deficiency in endothelial cell BH4 is alone sufficient to cause eNOS uncoupling, even in the absence of vascular diseases and in the presence of normal plasma BH4 levels.
The absolute dependence of endothelial NO production on endothelial cell BH4 availability was demonstrated by 3 complementary methods, each indicating deficient, or absent endothelial NO bioactivity in GCH1 fl/fl Tie2cre mice when compared with that in wild-type littermates. These include radiolabeled l-arginine to l-citrulline conversion using high-performance liquid chromatography detection of l-citrulline, nitrite/nitrate accumulation, and EPR detection of NO using Fe(DETC) 2 as spin trap. Despite this clear evidence of loss of endothelial NO generation in GCH1 fl/fl Tie2cre mice, endothelium-dependent vasodilatation to acetylcholine was only minimally impaired, suggesting that other eNOS-derived vasodilators are able to mediate vasodilatation when BH4 is limiting. We found that acetylcholine-induced vasodilatation in GCH1 fl/fl Tie2cre aortas is mediated by H 2 O 2 because PEG-catalase substantially inhibited vasodilatation in GCH1 fl/fl Tie2cre aortas and increased vascular H 2 O 2 production was quantified in GCH1 fl/fl Tie2cre aortas that was inhibited by L-NAME. These observations are consistent with the studies in aortas of mice with deoxycorticosterone acetate-salt hypertension 3 and in hph-1 mice with moderate systemic BH4 deficiency 6 although our new findings in GCH1 fl/fl Tie2cre mice overcome the lack of cell specificity in these previous models, and the potentially confounding effects of systemic changes, such as effects of BH4 deficiency on heart rate and sympathetic function in the hph-1 mouse. 14 Emerging evidence suggests that H 2 O 2 can mediate endothelium-dependent and endothelium-independent vasodilatation in several vascular beds in multiple species, including humans. 20-22 H 2 O 2 could mediate vasodilatation by endothelium-dependent smooth muscle hyperpolarization and vasodilatation, 17 or by activating sGC, leading to increased cGMP, or by directly activating PKG, and vasodilatation. [23] [24] [25] The mechanisms of H 2 O 2 -induced vasodilatation are varied depending on vascular beds and species. Our data suggest that eNOSderived H 2 O 2 production from uncoupled eNOS in GCH1 fl/fl Tie2cre aortas induces vasodilatation through sGC/PKG rather than through an endothelium-derived hyperpolarizing factor -independent pathway, as evidenced by the lack of inhibition by apamin and charybdotoxin, 18 or by 30 mmol/L extracellular K + , to inhibit the activity of Ca 2+ -activated K + channels. In contrast, the sGC inhibitor, ODQ, inhibited vasodilatation to acetylcholine in GCH1 fl/fl Tie2cre aortas to a similar extent as that observed in the presence of ODQ with PEG-catalase.
Previous evidence suggests that H 2 O 2 can induce eNOS expression. 3, 26, 27 Indeed, we found significantly greater eNOS protein in GCH1 fl/fl Tie2cre aortas, despite impaired vascular responses. These observations are consistent with reduced H 2 O 2 production in Nox4 -/mice, which reduced eNOS expression by 50%. 28 An alternative explanation for increased endothelial-derived O 2
•production may be a decrease in the protein levels of antioxidant enzymes (catalase, MnSOD, Cu/ZnSOD, and extracellular SOD). However, we found that the levels of these antioxidant enzymes were identical in both aortas and mesenteric vessels of GCH1 fl/fl Tie2cre and wild-type mice. Thus, the GCH1 fl/fl Tie2cre mouse reveals a new role for physiological BH4 levels in regulating eNOS-derived H 2 O 2 and in turn eNOS expression.
Although H 2 O 2 becomes a physiological mediator of eNOS-mediated vasorelaxations in the absence of BH4, this is not sufficient to compensate for loss of NO fully. Isometric tension studies in aortas and mesenteric arteries revealed increased responsiveness to phenylephrine that were equalized in the presence of L-NAME. Correspondingly, systolic blood pressure, measured both in conscious mice by tail-cuff plethysmography and in unconscious mice by Millar catheter, was higher in GCH1 fl/fl Tie2cre mice but was equalized by L-NAME treatment in drinking water. Furthermore, administration of phenylephrine under anesthesia caused a greater increase in systolic blood pressure in GCH1 fl/fl Tie2cre mice when compared with that in wild-type controls.
Acute administration of the SOD mimetic EUK-8 in anesthetized mice decreased blood pressure in wild-type mice but had little effect in GCH1 fl/fl Tie2cre mice. EUK-8 may act to reduce blood pressure in wild-type mice, where BH4 bioavailability is not limited, by scavenging basal ROS production, which in turn increases NO bioavailability. In contrast, GCH1 fl/fl Tie2cre have little endothelial NO bioactivity and vasorelaxations that are already dependent on eNOS-derived H 2 O 2 , such that the SOD mimetic drug alone has no significant effect on blood pressure.
To test the specificity of the observed phenotype for biochemical BH4 deficiency, we performed a rescue experiment using a BH4 precursor, sepiapterin. Ex vivo supplementation of GCH1 fl/fl Tie2cre aortas with sepiapterin restored endothelial function, abolishing eNOS-derived H 2 O 2 -mediated vasodilatation. This result is consistent with previous studies, demonstrating that supplementation with sepiapterin in hph-1 mice, 6 hypertensive mice, 3 chronic smokers, 29 and patients with diabetes mellitus 30 improved NO bioavailability and restored endothelial function. Previous studies of high-level pharmacological supplementation of exogenous BH4 have been criticized for nonspecific antioxidant effects. However, the present studies suggest that exogenous supplementation of BH4, using sepiapterin, can augment endothelial cell BH4 levels, at least in healthy animals. Targeted cell-specific mouse models of GCH1 deletion will be useful in future studies to test the effectiveness of in vivo strategies to restore or to supplement cellular BH4 levels.
In summary, we describe for the first time that selective deficiency in endothelial cell BH4 biosynthesis, by targeted GCH1 deletion, is alone sufficient to cause eNOS uncoupling, increased O 2
•production and reduced NO bioavailability, even in the absence of vascular disease and in the presence of normal plasma and systemic BH4 levels. This endothelial cell-autonomous requirement for BH4 biosynthesis is pivotal in maintaining eNOS-mediated NO versus H 2 O 2 signaling in vascular physiology and regulates systemic arterial blood pressure. The cell-autonomous requirement for endothelial cell BH4 has important implications for vascular disease states and therapeutic strategies aimed at augmenting vascular BH4.
Perspectives
The loss of BH4 in vascular wall is observed in patients and experimental models of hypertension and other vascular diseases, resulting in loss of NO and increased ROS production. Augmenting BH4 levels can prevent eNOS uncoupling and can improve endothelial dysfunction in vascular disease states. The present study now reveals that deficiency in endothelial cell BH4 biosynthesis is alone sufficient to cause eNOS uncoupling, endothelial dysfunction, and hypertension. Furthermore, normal plasma BH4 levels are not sufficient to rescue the loss of de novo BH4 biosynthesis in endothelial cells, revealing a cell-autonomous requirement for endothelial cell BH4 synthesis in the maintenance of BH4 levels in vivo. These findings suggest that targeting endothelial cell BH4 biosynthesis rather than systemic BH4 levels may be more relevant to the development and treatment of vascular diseases.
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None. • Endothelial cell-targeted GCH1 deletion leads to endothelial cell BH4 deficiency, despite no alteration in plasma BH4, revealing a cell-autonomous requirement for endothelial cell GCH1 and de novo BH4 biosynthesis in vivo.
• Endothelial cell BH4 plays a pivotal role in maintaining normal vascular function and in determining the formation of nitric oxide (NO) versus H 2 O 2 as alternative endothelial NO synthase (eNOS)-derived vasodilators.
• Endothelial cell-specific BH4 deficiency leads to hypertension.
What Is Relevant?
• GCH1 expression is a key determinant of endothelial cell BH4 levels, which are alone sufficient to regulate physiological eNOS function and blood pressure.
• Targeting endothelial cell BH4 biosynthesis rather than systemic BH4 levels may be more relevant to the development and treatment of hypertension.
Summary
Deficiency in endothelial cell BH4 biosynthesis, by targeted GCH1 deletion, is alone sufficient to cause eNOS uncoupling, increased O 2
•production, and reduced NO bioavailability, even in the absence of vascular disease and in the presence of normal plasma and systemic BH4 levels. This endothelial cell-autonomous requirement for BH4 biosynthesis is pivotal in maintaining eNOS-mediated NO versus H 2 O 2 signaling in vascular physiology and determines systemic arterial blood pressure. The cell-autonomous requirement for endothelial cell BH4 has important implications for vascular disease states and therapeutic strategies aimed at augmenting vascular BH4.
SUPPLEMENTAL METHODS
Genotyping GCH1 fl/fl ; Tie2cre loci
Mice were genotyped by polymerase chain reactions using DNA prepared from ear biopsies. For GCH1 fl/fl genotyping, PCR was performed using the following primers: GCH1 fl/fl -Fw 5'-GTC CTT GGT CTC AGT AAA CTT GCC AGG-3', GCH1 fl/fl -Rv 5'-GCC CAG CCA AGG ATA GAT GCA G-3'. The GCH1 floxed allele showed a 1030 bp. For Tie2cre genotyping, PCR was performed using the following primers: Tie2cre Fw 5'-GCA TAA CCA GTG AAA CAG CAT TGC TG-3'. Tie2cre Rv 5'-GGA CAT GTT CAG GGA TCG CCA GGC G-3'. The Tie2cre allele amplified as 280 bp fragment.
Isolation of Murine Endothelial Cells
Primary lung/heart endothelial cells were isolated using MACS beads (Miltenyi Biotec), as described previously 1 . Briefly, mice were culled by overdose of inhaled isoflurane. Lungs/heart were harvested and digested in DMEM containing 0.18 unit/ml Liberase TM (Roche) and 0.1 mg/ml Dnase I (Roche) for 1 hour at 37°C. The digested tissue was filtered through 100 μm and 70 μm cell strainers. The cell suspension was then incubated with rat anti-CD31 antibody (BD Pharmingen) for 15 minutes at 4°C then with anti-rat secondary antibody coated immune magnetic beads for further 15 minutes at 4°C. Bead-bound endothelial cells were selected using a magnetic column. All of experiments, endothelial cells were cultured for 5 days in getatin coated 12 well plates in EBM endothelial cell media.
Genomic DNA production and excision PCR
Genomic DNA for detection of the excised allele was produced using the QIAamp kit (Qiagen). The floxed and excised allele were detected using the following primers: 5'GTC CTT GGT CTC AGT AAA CTT GCC AGG3', 5'GCC CAG CCA AGG ATA GAT GCA G3', and 5'GCT CAT CCC CCA CAC TTG TCT T3'. The GCH1 floxed allele yields a1030 bp and the excised allele a production of 1392 bp.
Determination of Tissue Tetrahydrobiopterin Levels
BH4 and oxidised biopterins (BH2 and biopterin) were determined by high-performance liquid chromatography (HPLC) followed by electrochemical and fluorescent detection, respectively, following established protocol 2 . Briefly, snap frozen tissues (heart, lung, kidney, and liver) were homogenised and aortas were freeze-thawed in ice-cold resuspension buffer (50 mM phosphatebuffered saline, 1 mM dithioerythriol, 1 mM EDTA, pH 7.4). After centrifugation at 13,200 rpm for 10 min at 4°C, supernatant was removed and ice-cold acid precipitation buffer (1 M phosphoric acid, 2 M trichloroacetic acid, 1 mM dithioerythritol) was added. Following centrifugation at 13,200 rpm for 10 min at 4°C, the supernatant was removed and injected onto the HPLC system. Quantification of BH4 and oxidised biopterins was obtained by comparison with external standards and normalised to protein concentration, determined by the BCA protein assay.
Quantification of Intracellular Superoxide Production by Dihydroethidine HPLC
Superoxide production was quantified by measuring production 2-hydroxyethidium from dihydroethidium using HPLC 3, 4 . Briefly, primary endothelial cells were pre-incubated with serumfree DMEM (PAA) with or without 100 μM L-NAME (Sigma). Cells were then incubated with 25µM DHE (Invitrogen) for 20 min before being harvested for separation of DHE using gradient HPLC system (Jasco, UK) with an ODS3 reverse phase column (250mm, 4.5mm, Hichrom UK) and quantified using a fluorescence detector set at 510 nm (excitation) and 595 nm (emission).
Oxidative Fluorescent Microtopography
Endothelial superoxide production in mouse aortic frozen sections (n=6 per group) was detected using dihydroethidium (DHE) and fluorescent microscopy, as previously described 5 . Briefly, thoracic aortas (n = 6 per group) were harvested and frozen in optimal cutting temperature compound (OCT) (VWR International Ltd). Cryosections (30 µm) were cut at -25°C using a cryostat and placed on poly-lysine coated glass slide. Sections were incubated in KHB with or without 1 mM L-NAME for 30 min at 37 °C, then with 2 µM dihydroethidium (Invitrogen) for 5 min at 37°C in darkness. Sections were washed with ice-cold KHB, cover-slipped and placed in darkness. Images (x60) were acquired using a laser confocal microscope, set at identical acquisition settings (488 nm Excitation and 585 nm Emission). Endothelial superoxide production was quantified using Image-Pro Plus software by measuring the sum of the red intensities of the cells on the luminal side of the internal elastic lamina divided by the length of the vessel. For each ring, mean fluorescence was calculated from each quadrant of the vessels to produce n=1.
Analysis of NO Synthesis by eNOS
NO synthesis by eNOS was assessed by conversion of 14 C L-arginine to citrulline, in the presence and absence of N-monomethyl-L-arginine (1 mM, Sigma), as described previously 6 . Briefly, primary endothelial cells were incubated for 4 hours at 37°C in 200 μl Krebs-HEPES buffer containing 14 C L-arginine (2 μl of 50 μCi/mL). Samples were run on a SCX 300 cation-exchange HPLC column (Sigma) with online scintillation detection. Background signals were corrected from samples with 14 C L-arginine alone without cells.
Nitrite and Nitrate Determination
Freshly harvested aortas were preincubated in the presence or absence of L-monomethylarginine (100 μM, Sigma) in Krebs-Henseleit buffer (120 mM NaCl, 4.7 mM KCl, 1.2 mM MgSO4, 1.2 mM KH2PO4, 2.5 mM CaCl2, 25 mM NaHCO3, and 5.5 mM glucose) at 37°C, then exposed to acetylcholine (1 µM) for 30 min. Nitrite and nitrate accumulation was measured in samples of buffer using the CLD88 NO analyzer (Ecophysics) and normalized to aortic dry weight.
Determination of Aortic NO Production by Electron Paramagnetic Resonance
Electron paramagnetic resonance (EPR) spectroscopy was used to quantify aortic NO production, as described previously 7 . Briefly, freshly harvested aortas were stimulated with acetylcholine (1 μM) in 100 μl Krebs-HEPES buffers, then incubated with colloid iron (II) diethyldithiocarbamate [Fe(DETC) 2 ] (285 µmol/L) at 37°C for 90 minutes. After incubation, aortas were snap-frozen in a column of Krebs-HEPES buffer in liquid nitrogen, and EPR spectra were obtained using an X-band EPR spectrometer (Miniscope MS 200; Magnettech). Instrument settings were: centre-field (B 0 ) 3276G, sweep 115G, microwave power 10 mW, modulation frequency 100 kHz, amplitude modulation 8000 mG, sweep time 60 s, and number of scans 4. Signals were quantified by measuring the total amplitude, after correction of baseline, and after subtracting background signals from incubation with colloid Fe(DETC) 2 alone. Values were normalized to aortic dry weight.
Determination of Aortic H 2 O 2 Production
Aortic H 2 O 2 production was determined by Amplex red assay (Molecular Probes), as described previously 8 . Briefly, freshly harvested aortic rings (6 x 2 mm) were incubated in 50 μl KHB containing 2 μM Ach, at 37°C for 60 minutes in dark, with or without 100 μM L-NAME. After incubation, 50 μl of Amplex Red reagent mixture containing 20 mM Amplex red, 0.4 U/ml horseradish peroxidase. Buffer fluorescence was determined at excitation 530 nm and emission 590 nm. Background fluorescence (without vessels) was subtracted and normalized to aortic dry weight.
Measurement of Arterial Blood Pressure
Blood pressure in conscious wild-type and GCH1 fl/fl Tie2cre mice was measured using the Visitech R tail-cuff plethysmography system following 5 days training and 3 days baseline periods. In unconscious mice, blood pressure was measured in anesthetized wild-type and GCH1 fl/fl Tie2cre mice using the Millar catheter system, as described previously 1 .
Isometric Tension Vasomotor Studies
Vasomotor function was analyzed using isometric tension studies in a wire myograph (Multi-Myogrph 610M, Danish Myo Technology, Denmark). Briefly, vascular rings were isolated from the thoracic aorta. The aortic rings or 2 nd mesenteric arteries (2 mm) were mounted on a wire myograph containing 5 ml of Krebs-Henseleit buffer (KHB [in mmol/l]: NaCl 120, KCl 4.7, MgSO 4 1.2, KH 2 PO 4 1.2, CaCl 2 2.5, NaHCO 3 25, glucose 5.5) at 37°C, gassed with 95% O 2 /5% CO 2 . After allowing vessels to equilibrate for 30 minutes, the optimal tension was set. All experiments with aortas were performed in the presence of 10 μM non-selective cyclooxygenase (COX) inhibitor indomethacin (to block prostacyclin synthesis). The vessel viability was tested using 60 mM KCl. Concentration-response contraction curves were established using cumulative half-log concentrations of phenylephrine or U46619. Vessels were washed three times with fresh KHB, equilibrated for 20 minutes, and then precontracted to approximately 80-90% of maximal tension with PE or U46619. Acetylcholine and SLIGRL were used to stimulate endothelium-dependent vasodilatations in increasing cumulative concentrations. Responses were expressed as a percentage of the precontracted tension. Finally, the NO donor sodium nitroprusside (SNP) was used to test endothelium-independent smooth muscle relaxation in the presence of L-NAME. All pharmacological drugs were pre-incubated at least 20 min before the dose-response curves were determined. PEG-catalase was used at 400 units/ml, apamin at 50 nM, charybdotoxin at 100 nM, 1H-(1,2,4)oxadiazolo[4,3-a]quinoxalin-1-one (ODQ) at 500 nM, indomethacin at 10 µM, L-NAME at 100 µM and sepiapterin at 10 µM. All drugs used were purchased from Sigma Chemical Company except ODQ (Cayman Europe) and SLIGRL (Abcam). 
